Uniphar Stock

Uniphar FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Uniphar (UPR.IR) as of Aug 5, 2026 is 89.29 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 34.55 % — a change of 158.45% (higher).

FCF Conversion

89.29 %

YoY

158.45%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Uniphar is 2026 89.29 % . FCF Conversion Rate (FCF/EBITDA) of Uniphar was 2025 34.55 % . It decreases by 158.45% higher compared to the previous year.
Access this data via the Eulerpool API

Uniphar Stock analysis

What does Uniphar do? Uniphar PLC is an Irish company that was founded in 1994 and operates in the healthcare industry. The company is headquartered in Dublin and employs over 2,500 people worldwide. The history of Uniphar began as a pharmacy distribution company that supplied medications to retailers and healthcare facilities. Over the years, however, the company has expanded its business model and now offers a wide range of healthcare products and services. Uniphar's business model encompasses three main areas: Healthcare Services, Commercial & Clinical Supply Chain, and Product Access & Specialty Medicines. In the Healthcare Services area, Uniphar provides consulting services, training, and leadership coaching for healthcare facilities. The Commercial & Clinical Supply Chain division includes the storage, logistics, and distribution of medications, as well as the clinical care of patients. The Product Access & Specialty Medicines division focuses on access to medications with high medical demand and rare diseases. Uniphar also offers a wide range of healthcare products, including generics, branded medications, and medical devices. The company has partnerships with leading pharmaceutical companies such as Pfizer, Eli Lilly, and Merck. In recent years, Uniphar has also made several significant acquisitions to expand and diversify its business. In 2018, the company acquired UK-based pharmaceutical distributor Cahill May Roberts, and in 2019, the acquisition of Durbin, an international supplier of clinical supply products, was completed. Uniphar is committed to improving healthcare in Ireland and worldwide and offers a wide range of products and services to achieve this goal. The company has earned a reputation as a reliable partner for healthcare facilities and pharmaceutical companies and is on a steady growth trajectory. Uniphar is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uniphar stock

FCF Conversion Rate (FCF/EBITDA) of Uniphar is 89.29 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Uniphar changed from 34.55 % to 89.29 %, representing a 158.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Uniphar since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Uniphar with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Uniphar

All Key Metrics — Uniphar